This site is intended for healthcare professionals
Drug information


Read time: 24 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Doxorubicin is a cytotoxic medicinal product that is indicated in the following neoplastic conditions:

• Small-cell lung cancer (SCLC)

• Breast cancer

• Recurrent ovarian carcinoma

• Systemic treatment of local advanced or metastasized bladder carcinoma

• Intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection

• Neoadjuvant and adjuvant therapy of osteosarcoma

• Advanced soft-tissue sarcoma in adults

• Ewing's sarcoma

• Hodgkin's disease

• Non-Hodgkin's lymphoma

• Acute lymphatic leukaemia

• Acute myeloblastic leukaemia

• Advanced multiple myeloma

• Advanced or recurrent endometrial carcinoma

• Wilms' tumour

• Advanced papillary/follicular thyroid cancer

• Anaplastic thyroid cancer

• Advanced neuroblastoma

Doxorubicin is frequently used in combination chemotherapy regimens with other cytostatic medicinal products.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).